PGD2-CRTH2 pathway promotes tubulointerstitial fibrosis

Journal of the American Society of Nephrology

Volumn 23, Issue 11, 2012, Pages 1797-1809

  Ito, Hideyuki ^a,b   Yan, Xiaoxiang ^a   Nagata, Nanae ^c   Aritake, Kosuke ^c   Katsumata, Yoshinori ^a   Matsuhashi, Tomohiro ^a   Nakamura, Masataka ^d   Hirai, Hiroyuki ^e   Urade, Yoshihiro ^c   Asano, Koichiro ^a   Kubo, Masato ^f   Utsunomiya, Yasunori ^b   Hosoya, Tatsuo ^b   Fukuda, Keiichi ^a   Sano, Motoaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA BIOSCIENCE INSTITUTE   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e Kawagoe shi   (Japan)

^f INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAY 10471; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON TH2 CELLS RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 4; LIPOCALIN; LIPOCALIN TYPE PROSTAGLANDIN D2 SYNTHASE; PROSTAGLANDIN D2; PROTEIN INHIBITOR; RECEPTOR; SYNTHETASE; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; ISOMERASE; MESSENGER RNA; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN R2 D ISOMERASE; PROSTAGLANDIN R2 D-ISOMERASE; PROSTAGLANDIN RECEPTOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH2 CELL; URETER OBSTRUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; FIBROSIS; GENETICS; HUMAN; IMMUNOLOGY; KIDNEY DISEASE; METABOLISM; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARBAZOLES; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY DISEASES; LIPOCALINS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTAGLANDIN D2; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONAMIDES; TH2 CELLS; URETERAL OBSTRUCTION;

EID: 84868618444     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012020126     Document Type: Article

References (41)

1. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20: 1-17, 1992
2. Harris RC, Neilson EG: Toward a unified theory of renal progression. Annu Rev Med 57: 365-380, 2006 (Pubitemid 43261996)
3. Bohle A, Strutz F, Müller GA: On the pathogenesis of chronic renal failure in primary glomerulopathies: A view from the interstitium. Exp Nephrol 2: 205-210, 1994 (Pubitemid 24201686)
4. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB: Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22: 1144-1151, 2011
5. Hirawa N, Uehara Y, Ikeda T, Gomi T, Hamano K, Totsuka Y, Yamakado M, Takagi M, Eguchi N, Oda H, Seiki K, Nakajima H, Urade Y: Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus. Nephron 87: 321-327, 2001 (Pubitemid 32260832)
6. Hamano K, Totsuka Y, Ajima M, Gomi T, Ikeda T, Hirawa N, Eguchi Y, Yamakado M, Takagi M, Nakajima H, Oda H, Seiki K, Eguchi N, Urade Y, Uehara Y: Blood sugar control reverses the increase in urinary excretion of prostaglandin D synthase in diabetic patients. Nephron 92: 77-85, 2002 (Pubitemid 34983879)
7. Hirawa N, Uehara Y, Yamakado M, Toya Y, Gomi T, Ikeda T, Eguchi Y, Takagi M, Oda H, Seiki K, Urade Y, Umemura S: Lipocalin-type prostaglandin d synthase in essential hypertension. Hypertension 39: 449-454, 2002 (Pubitemid 34168205)
8. Nagata N, Fujimori K, Okazaki I, Oda H, Eguchi N, Uehara Y, Urade Y: De novo synthesis, uptake and proteolytic processing of lipocalin-type prostaglandin D synthase, beta-trace, in the kidneys. FEBS J 276: 7146-7158, 2009
9. Tsuchida T, Eguchi N, Eguchi Y, Numabe A, Nakajima H, Oda H, Seiki K, Hakamada-Taguchi R, Urade Y, Uehara Y: Lipocalin-type prostaglandin D synthase in urine in adriamycin-induced nephropathy of mice. Nephron Physiol 96: 42-51, 2004
10. GilesH, Leff P, Bolofo ML, Kelly MG, Robertson AD: The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol 96: 291-300, 1989 (Pubitemid 19045102)
11. Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, Eguchi N, Urade Y, Yoshida N, Kimura K, Mizoguchi A, Honda Y, Nagai H, Narumiya S: Prostaglandin D2 as a mediator of allergic asthma. Science 287: 2013-2017, 2000
12. Gosset P, Pichavant M, Faveeuw C, Bureau F, Tonnel AB, Trottein F: Prostaglandin D2 affects the differentiation and functions of human dendritic cells: Impact on the T cell response. Eur J Immunol 35: 1491-1500, 2005 (Pubitemid 40691431)
13. Tanaka K, Hirai H, Takano S, Nakamura M, Nagata K: Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res Commun 316: 1009-1014, 2004 (Pubitemid 38369053)
14. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K: Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193: 255-261, 2001 (Pubitemid 32524457)
15. Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MG, Pettipher R: Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 175: 6531-6536, 2005 (Pubitemid 41598895)
16. Chevalier RL, Forbes MS, Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75: 1145-1152, 2009
17. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA: Chronic renal allograft dysfunction: The role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 15: 390-397, 2004 (Pubitemid 38140779)
18. Strutz F, Neilson EG: The role of lymphocytes in the progression of interstitial disease. Kidney Int Suppl 45: S106-S110, 1994
19. Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, Kretzler M, Strutz F, Mack M, Gröne HJ, Onuffer J, Horuk R, Nelson PJ, Schlöndorff D: A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 109: 251-259, 2002 (Pubitemid 34083745)
20. Eis V, Luckow B, Vielhauer V, Siveke JT, Linde Y, Segerer S, Perez De Lema G, Cohen CD, Kretzler M, Mack M, Horuk R, Murphy PM, Gao JL, Hudkins KL, Alpers CE, Gröne HJ, Schlöndorff D, Anders HJ: Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 15: 337-347, 2004 (Pubitemid 38140774)
21. Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W: Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int 78: 351-362, 2010
22. Cheever AW, Williams ME, Wynn TA, Finkelman FD, Seder RA, Cox TM, Hieny S, Caspar P, Sher A: Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol 153: 753-759, 1994 (Pubitemid 24206304)
23. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA: An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104: 777-785, 1999 (Pubitemid 29536363)
24. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR: Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 28: 2619-2629, 1998 (Pubitemid 28425221)
25. Blease K, Jakubzick C, Westwick J, Lukacs N, Kunkel SL, Hogaboam CM: Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol 166: 5219 -5224, 2001
26. Keane MP, Gomperts BN, Weigt S, Xue YY, Burdick MD, Nakamura H, Zisman DA, Ardehali A, Saggar R, Lynch JP 3rd, Hogaboam C, Kunkel SL, Lukacs NW, Ross DJ, Grusby MJ, Strieter RM, Belperio JA: IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol 178: 511 -519, 2007
27. Kolodsick JE, Toews GB, Jakubzick C, Hogaboam C, Moore TA, McKenzie A, Wilke CA, Chrisman CJ, Moore BB: Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 172: 4068-4076, 2004 (Pubitemid 38375218)
28. Fertin C, Nicolas JF, Gillery P, Kalis B, Banchereau J, Maquart FX: Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol 37: 823-829, 1991
29. Doucet C, Brouty-Boyé D, Pottin-Clémenceau C, Canonica GW, Jasmin C, Azzarone B: Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 101: 2129-2139, 1998 (Pubitemid 28244097)
30. Tiggelman AM, Boers W, Linthorst C, Sala M, Chamuleau RA: Collagen synthesis by human liver (myo)fibroblasts in culture: Evidence for a regulatory role of IL-1 beta, IL-4, TGF beta and IFN gamma. J Hepatol 23: 307-317, 1995
31. Ragolia L, Palaia T, Hall CE, Maesaka JK, Eguchi N, Urade Y: Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice. J Biol Chem 280: 29946-29955, 2005 (Pubitemid 41177073)
32. Zhang A, Dong Z, Yang T: Prostaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells. Am J Physiol Renal Physiol 291: F1332-F1342, 2006 (Pubitemid 44887247)
33. Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa H, Kakudo S, Ohtani M, Arita H: Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 298: 411-419, 2001 (Pubitemid 32673391)
34. Faveeuw C, Gosset P, Bureau F, Angeli V, Hirai H, Maruyama T, Narumiya S, Capron M, Trottein F: Prostaglandin D2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur J Immunol 33: 889-898, 2003 (Pubitemid 36546676)
35. Snelgrove SL, Kausman JY, Lo C, Lo C, Ooi JD, Coates PT, Hickey MJ, Holdsworth SR, Kurts C, Engel DR, Kitching AR: Renal dendritic cells adopt a pro-inflammatory phenotype in obstructive uropathy to activate T cells but do not directly contribute to fibrosis. Am J Pathol 180: 91-103, 2012
36. Eguchi N, Minami T, Shirafuji N, Kanaoka Y, Tanaka T, Nagata A, Yoshida N, Urade Y, Ito S, Hayaishi O: Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci U S A 96: 726-730, 1999 (Pubitemid 29061276)
37. Tanaka S, Motomura Y, Suzuki Y, Yagi R, Inoue H, Miyatake S, Kubo M: The enhancer HS2 critically regulates GATA-3-mediated Il4 transcription in T(H)2 cells. Nat Immunol 12: 77-85, 2011
38. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44(2):313-321, 1993 (Pubitemid 23228685)
39. Liang F, Hatanaka Y, Saito H, Yamamori T, Hashikawa T: Differential expression of gamma-aminobutyric acid type B receptor-1a and -1b mRNA variants in GABA and non-GABAergic neurons of the rat brain. J Comp Neurol 416: 475-495, 2000 (Pubitemid 30033488)
40. Komatsu Y, Watakabe A, Hashikawa T, Tochitani S, Yamamori T: Retinol-binding protein gene is highly expressed in higher-order association areas of the primate neocortex. Cereb Cortex 15: 96 -108, 2005
41. Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA: Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem 283: 1179-1188, 2008